Who
Jason Tardio
President and COO
Company insider
Files Form 4 as: President and COO, Immunic; Chief Operating Officer, Ovid Therapeutics.
In numbers
- Trades disclosed
- 26
- Buys
- 2
- Sells
- 1
- Bought
- $20K
- Sold
- $37K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 18 Nov 2019
- Last trade
- 29 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 29 Jun 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —253,000 at $0.00 | filing |
| 29 Jun 2026filed 29 Jun 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —253,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —660,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —660,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,000 at $0.00 | filing |
| 16 Jul 2025filed 18 Jul 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,000 at $0.00 | filing |
| 5 Jun 2025filed 20 Jun 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —598,500 at $0.00 | filing |
| 5 Jun 2025filed 20 Jun 2025 | IMUX ImmunicBiotechnology | SEC FORM 4 Bought | $9,88412,512 at $0.79 | filing |
| 5 Jun 2025filed 9 Jun 2025 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —595,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | IMUX ImmunicBiotechnology | SEC FORM 4 Bought | $9,88412,512 at $0.79 | filing |
| 4 Dec 2024filed 6 Dec 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —157,500 at $0.00 | filing |
| 12 Jul 2024filed 12 Jul 2024 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 22 Feb 2024filed 26 Feb 2024 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —168,750 at $0.00 | filing |
| 22 Feb 2024filed 26 Feb 2024 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Code A | —28,125 at $0.00 | filing |
| 23 Feb 2023filed 27 Feb 2023 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 12 Sep 2022filed 14 Sep 2022 | OVID Ovid TherapeuticsBiotechnology | SEC FORM 4 Sold | $37K17,344 at $2.15 | filing |
| 8 Apr 2022filed 12 Apr 2022 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,498 at $0.00 | filing |
| 8 Apr 2022filed 12 Apr 2022 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Feb 2022filed 4 Feb 2022 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
News
Ovid Therapeutics (NASDAQ:OVID) Stock Rated "Overweight" in New Coverage at Cantor FitzgeraldOVID · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Jason Tardio; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.